FocalTherics (NASDAQ:FOCL) Director Lance Willsey Buys 50,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) Director Lance Willsey purchased 50,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the transaction, the director directly owned 1,291,780 shares in the company, valued at approximately $6,135,955. This represents a 4.03% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

FocalTherics Trading Down 8.4%

Shares of FocalTherics stock opened at $4.36 on Tuesday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The company’s fifty day moving average price is $5.38. The stock has a market capitalization of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. Analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. SmartHarvest Portfolios LLC acquired a new stake in FocalTherics in the first quarter valued at approximately $38,000. Lido Advisors LLC purchased a new stake in shares of FocalTherics during the 1st quarter valued at $40,000. Kovack Advisors Inc. acquired a new stake in shares of FocalTherics in the 4th quarter worth $53,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics in the 4th quarter worth $313,000. Finally, Flax Pond Capital LLC purchased a new position in FocalTherics during the 4th quarter worth $2,623,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

FocalTherics News Summary

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on FOCL. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.